Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onvansertib + FOLFIRI + Bevacizumab in KRAS-mutated mCRC
NCT03829410Phase 2Completed
- Sponsor
- Cardiff Oncology
- Start
- Jun 2019
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of onvansertib in metastatic colorectal cancer (mCRC), sponsored by Cardiff Oncology. Started Jun 2019; status: completed.
02
Drugs
onvansertib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03829410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829410.